Clinical trial · Observational
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
The First Affiliated Hospital, Zhejiang University School of Medicine
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention, observation study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Donors aged 40 years or older
- interventionNames
- Other: No intervention, observation study
- label
- Donors aged < 40
- interventionNames
- Other: No intervention, observation study
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of transplantuntil the date of death from any cause, assessed up to 60 months.
- description
- The duration from transplant until death resulted from any cause.
Secondary outcomes (2)
- measure
- Relapse-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 5 years * First allo-HSCT from matched related, unrelated, or haploidentical donors * Achievement of complete remission after allo-HSCT * Donor blood sample collection before granulocyte colony-stimulating factor mobilization Exclusion Criteria * Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia * Failure to achieve engraftment with full donor chimerism after allo-HSCT * Inability to extract DNA for telomere length analysis.
References
Publications (0)
Data not yet available